KA Imaging Unveils New Brand Identify for its Patented Dual Energy Technology

SpectralDR™ is built into the Reveal™ 35C detector and family of products

Canadian manufacturer KA Imaging unveiled a new brand identity for its patented dual-energy technology. SpectralDR™ is currently built into the Reveal™ 35C detector. The new brand is in line with the company’s strategy to expand its presence in the X-ray market.

“The Reveal™ 35C detector is a breakthrough and the first in an exciting product roadmap,” said Fernanda Fraga, Marketing Manager of KA Imaging. At this time, Reveal™ 35C detector is available for sale in Canada, the United States, and other countries globally. Earlier this year, the company announced plans to develop an integrated mobile system powered by its SpectralDR™ technology.

KA Imaging’s SpectralDR™ technology enables dual-energy subtraction, providing bone and tissue differentiation with a single standard X-ray exposure. It acquires three images simultaneously (DR, bone and soft tissue dual-energy X-ray images). The technology mimics the workflow, dose and techniques of state-of-the-art mobile DR X-ray detectors.

“It’s a 3-in-1 solution, as in three images with one exposure to radiation and no extra work. Having a DR plus the supplemental spectral bone and tissue images allows for better diagnosis and faster reading,” said Dr. Phil Templeton, radiologist, and Chief Medical Officer of KA Imaging. The spectral images provide enhanced visualization of different conditions like lung nodules, pneumonia, tips of lines and tubes, pneumothorax and retained surgical bodies.

Adding a name to the patented technology simplifies the message to the industry. “SpectralDR™ addresses the drawbacks of previous dual-energy subtraction or bone suppression approaches,” said Dr. Karim S. Karim, CTO of KA Imaging.  Conventional dual energy is not mobile and uses two exposures, while bone suppression image quality is limited and cannot provide bone images. “SpectralDR™ really takes general X-ray to the next level because you can get true bone and soft tissue subtracted images every time plus a DR image in one exposure at the lowest dose. If it’s low dose, 3-in-1, and mobile and single exposure, you can bet it is powered by SpectralDR™, said Karim.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.